NICE says final fast-tracked yes to Napp's Levact
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has given a final thumbs up to Napp Pharmaceuitcals's Levact (bendamustine) for some patients with chronic lymphocytic leukaemia (CLL).